Anti-GD2 antibody therapy: An important approach in the treatment of neuroblastoma
In this recorded session from Solving Kids' Cancer UK's 2022, Dr Robbie Majzner and Prof Juliet Gray explore the role of anti-GD2 antibody therapy in the treatment of neuroblastoma. Dr Majzner provides an overview of the history of anti-GD2 and his research into combination therapies, while Prof Gray shares insights from clinical research and discusses clinical trials, including BEACON Immuno and MiNivAN.
Looking for something else?
-
Need to speak with someone?Get in touch with our Family Support Team.
-
Help and supportHead to our Help and Support homepage to see how we can support you.
-
Refractory neuroblastomaFind all the information on refractory neuroblastoma in one place.
-
Relapsed neuroblastomaFind all the information on relapsed neuroblastoma in one place.
Related videos
-
Video (2025)Treating relapsed and refractory disease
An overview of clinical trials and new treatments for relapsed and refractory neuroblastoma.
-
Video (2026)Understanding current frontline treatment
Overview of how high-risk neuroblastoma is treated in the US and Europe, including current frontline approaches through COG and SIOPEN.